RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SymBio Pharmaceuticals Stock

SymBio Pharmaceuticals Equity 2024

SymBio Pharmaceuticals Equity

7.21 B JPY

Ticker

4582.T

ISIN

JP3383050006

WKN

A1JMJE

In 2024, SymBio Pharmaceuticals's equity was 7.21 B JPY, a -15.24% increase from the 8.51 B JPY equity in the previous year.

SymBio Pharmaceuticals Aktienanalyse

What does SymBio Pharmaceuticals do?

SymBio Pharmaceuticals Ltd is a company specializing in the development and marketing of medical products. The company, based in Japan, was founded in 2005 and currently employs over 300 employees. SymBio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing SymBio Pharmaceuticals's Equity

SymBio Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SymBio Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SymBio Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SymBio Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SymBio Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SymBio Pharmaceuticals stock

What is the equity of SymBio Pharmaceuticals this year?

SymBio Pharmaceuticals has equity of 7.21 B JPY this year.

What was the equity of SymBio Pharmaceuticals compared to the previous year?

The equity of SymBio Pharmaceuticals has increased/decreased by -15.24% decreased compared to the previous year.

What impact does a high equity have on investors of SymBio Pharmaceuticals?

A high equity is advantageous for investors of SymBio Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of SymBio Pharmaceuticals?

A low equity can be a risk for investors of SymBio Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of SymBio Pharmaceuticals affect the company?

An increase in equity of SymBio Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of SymBio Pharmaceuticals affect the company?

A reduction in equity of SymBio Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of SymBio Pharmaceuticals?

Some factors that can affect the equity of SymBio Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of SymBio Pharmaceuticals so important for investors?

The equity of SymBio Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can SymBio Pharmaceuticals take to change the equity?

To change equity, SymBio Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does SymBio Pharmaceuticals pay?

Over the past 12 months, SymBio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SymBio Pharmaceuticals is expected to pay a dividend of 0 JPY.

What is the dividend yield of SymBio Pharmaceuticals?

The current dividend yield of SymBio Pharmaceuticals is .

When does SymBio Pharmaceuticals pay dividends?

SymBio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SymBio Pharmaceuticals?

SymBio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of SymBio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SymBio Pharmaceuticals located?

SymBio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von SymBio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SymBio Pharmaceuticals from 8/31/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 8/31/2024.

When did SymBio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/31/2024.

What was the dividend of SymBio Pharmaceuticals in the year 2023?

In the year 2023, SymBio Pharmaceuticals distributed 0 JPY as dividends.

In which currency does SymBio Pharmaceuticals pay out the dividend?

The dividends of SymBio Pharmaceuticals are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SymBio Pharmaceuticals

Our stock analysis for SymBio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SymBio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.